ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.

A peer-reviewed study led by Aalborg University has found that the seismocardiography technology behind Acarix’s CADScor System can detect heart failure with diagnostic accuracy comparable to a standard blood test, and with substantially fewer false positives – a condition distinct from the coronary artery disease the device is currently cleared for.

The US FDA has granted Orphan Drug Designation to Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for the treatment of endogenous Cushing’s syndrome, adding to a growing list of rare-disease designations for the candidate across three regions.

RaySearch Laboratories and US-based Accuray have entered a definitive agreement to expand their collaboration on online adaptive radiation therapy, with Accuray committing to purchase RayStation software licences worth USD 8 million.

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company’s continued market expansion.

Neola Medical has been granted Breakthrough Device Designation by the US FDA for Neola, its non-invasive lung monitor for preterm babies, designed to give early warning of life-threatening lung collapse.

Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, BioArctic’s partner Eisai announced.

The company has completed a directed share issue as it approaches proof-of-concept data from its Phase IIa study in chronic kidney disease with anemia, expected around the turn of the year.

Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible Canadian patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, BioArctic’s partner Eisai announced. The Swedish biotech invented the antibody and holds commercialisation rights to it in the Nordic region.

A large population study using NADMED’s redox metabolite testing platform has established healthy reference ranges for NAD and glutathione, two key drivers of cellular energy metabolism, and identified distinct disease-related alterations in both from a single blood sample.

Researchers at the University of Gothenburg have developed a treatment for acute myeloid leukemia that forces cancer cells to run at full throttle while cutting off their energy supply, driving them to burn out and die from the stress. The first study in mice shows highly promising results.

Ada Yonath, the 2009 Nobel laureate in Chemistry, died on August 31, 2026, at the age of 87. She was one of the first Nobel Prize laureates I interviewed as a new editor at Nordic Life Science – and the first I met in person, over an interview at the Grand Hotel in Stockholm. Yonath, who in 2009 became the first woman in 45 years to win the Nobel Prize in Chemistry, spoke to me about her curiosity, polar bears, extremely durable bacteria from the Black Sea, and her passion for science.